A PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN ≥5 TO <12 YEARS OF AGE

This Study is
No Longer Enrolling

Description

In this new study, we will learn if the vaccine can produce an immune response against COVID-19, and if it is safe, in children 5-11 years old. All participants will have the opportunity to receive the COVID-19 study vaccine during their time in the trial.

Details
Age

Child

Eligibility

Healthy Children Ages 5-11 Years Old

Type of Study

Treatment

Locations

Childrens Hospital Colorado

Study ID

Protocol Number: 21-2841

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers